Yüklüyor......

Optimizing therapy for mantle cell lymphoma

Most people with mantle cell lymphoma (MCL) present with diffuse adenopathy and benefit from early initiation of rituximab and high-dose cytarabine- or bendamustine-based therapies. Some patients, however, present with primarily nonnodal disease that can follow either an indolent or a rapidly progre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hematology Am Soc Hematol Educ Program
Yazar: Martin, Peter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2017
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142585/
https://ncbi.nlm.nih.gov/pubmed/29222271
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!